The marked improvement in PD scores in patients 5 and 6 after treatment with methotrexate plus infliximab and relatively low total PD scores in patients receiving treatment with methotrexate plus TNF antagonists (patients 3, 4, 7, and 9) support the notion that a methotrexate plus TNF antagonist regimen is efficacious not only for RA[40,41] and JIA[42] but also for arthritis in patients with Blau syndrome[43]. The gene discussed is TNF; the disease is juvenile idiopathic arthritis.